期刊
PEDIATRIC BLOOD & CANCER
卷 69, 期 4, 页码 -出版社
WILEY
DOI: 10.1002/pbc.29557
关键词
brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse
Combination therapy with brentuximab vedotin and bendamustine may be a suitable salvage therapy for children and young adults with Hodgkin's lymphoma, showing a high overall response rate and 3-year survival rate.
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据